Onconetix, Inc. (ONCO), a commercial-stage biotechnology company, on Wednesday announced that it has entered into a definitive merger agreement to acquire Ocuvex Therapeutics, Inc. The deal is expected to close in the fourth quarter of 2025.
The companies agreed that Onconetix would acquire all of Ocuvex's equity.
After the deal closes, Ocuvex holders will own 90% of the combined company, while Onconetix shareholders will keep 10%, with possible adjustments if new funding is raised.
The new board will have seven members, five chosen by Ocuvex and two by Onconetix.
Chairman of the Board of Onconetix Andrew J. Oakley said the company remains confident that the proposed transaction with Ocuvex, which includes a pipeline of commercial and late-stage ophthalmic assets, will deliver substantial value to stockholders.
Onconetix is currently trading 6.21% higher at $3.4500 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.